Physician profile
John E Oxler
NPI 1083619555
$8,775.94
in general payments reported to CMS, 2019-2025
63 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $941 · 2021: $1,016 · 2022: $1,886 · 2023: $1,621 · 2024: $1,782 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,494.47 | 2020-2025 | |
| Novo Nordisk INC | $840.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $820.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $629.42 | 2019-2025 | |
| Amgen INC. | $485.81 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $431.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.97 | 2019-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Abbott Laboratories | $179.58 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $173.99 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $169.24 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $161.07 | 2021-2023 | |
| Astellas Pharma US INC | $152.59 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $144.70 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $138.37 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $130.25 | 2023-2024 | Gemtesa |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oxler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.